11 glimepiride). GUIDE study: gliclazide MR vs.
18 Apr 2007 diabetes in the elderly,5 although there is no evidence from controlled studies to supports this. While there University of York Centre for Reviews and Dissemination (CRD) databases, ECRI's. HTAIS .. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic
(A. Grimaldi); Policlinico Umberto I, Rome, Italy (U. Di Mario); Medical University of Lodz, Lodz, Poland (J. Drzewoski); Semmelweis GUIDE (GlUcose control in type 2 diabetes: Diamicron MR vs. glimEpiride) is a large scale prospective double-blind, randomized study comparing gliclazide MR and glimepiride, over.
The GUIDE study (GlUcose control In type 2 diabetes: Diamicron MR versus glimEpiride) was carried out in 845 type 2 diabetic patients according to a double-blind, 27-week, parallel-group design. At the end of the follow-up, HbA1c had decreased by 1.3% in newly diagnosed patients treated with gliclazide MR in
28 May 2014 randomized trial, including frequent patienta physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study Mohamed Hassanein,1 Khalifa Abdallah,2 Anja Schweizer31Betsi Cadwaladr University
12 Feb 2014 The aim of this study was to assess in a systematic review and meta-analysis of randomized controlled trials the safety and efficacy of gliclazide compared to other oral glucose-lowering (2004) GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients.
Historically, in 1960, the University Group Diabetes Program (UGDP) reported an increased risk of all-cause and CV mortality with tolbutamide; despite the fact that, .. The European GUIDE (GlUcose control in type 2 diabetes: Diamicron MR vs. glimepiride) study (n = 845) was the first double-blind, 27-week, parallel-group

Annons

The photo has no tags

February 2018